RPG Life Sciences share news, announcements and annual reports
NSE: RPGLIFEBSE: 532983Pharmaceuticals & BiotechnologySmall Cap
RPG Life Sciences Limited · Face value ₹8 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 2008
Last close ₹2,575.70down ₹428.10 (14.25%)BSE ₹2,572.40
Share price at the NSE close on 30 Oct 2026. Previous close ₹3,003.80.
30 Oct: open ₹2,812.00, high ₹2,849.60, low ₹2,513.50
52-week range of traded prices to 30 Oct 2026
₹1,733.00Low, 23 Mar 2026₹3,127.80High, 25 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,260 Cr923rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.94
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.20
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.93%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it, the company's own balance sheet from before it began consolidating; the two agree where both are first on record.
- 17.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 14.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,38,78323.6% delivered
RPG Life Sciences share news and announcements
681 announcements, routine notices left out, newest first. Page 8 of 14.
Jun 2019
11 Jun · Analysts
May 2019
22 May · Related Party Transactions
Apr 2019
29 Apr · Results
29 Apr · Board meeting
22 Apr · Board meeting
Mar 2019
15 Mar · Updates
Feb 2019
12 Feb · Meeting
5 Feb · Results
5 Feb · Board meeting
Jan 2019
29 Jan · Board meeting
Nov 2018
5 Nov · Results
5 Nov · Board meeting
Oct 2018
29 Oct · Board meeting
Sep 2018
27 Sep · Updates
27 Sep · Board meeting
Aug 2018
Jul 2018
27 Jul · Meeting
27 Jul · Board meeting
27 Jul · Results
2 Jul · Meeting
Jun 2018
13 Jun · Analysts
May 2018
8 May · Legal
Exchange has sought clarification from RPG Life Sciences Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of Equity not submitted The response of the Company is awaited.2 May · Board meeting